- Home
- NCSM vs CNTB Comparison
NCSM vs CNTB Comparison
Compare NCSM & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NCSM | CNTB |
|---|---|---|
| Founded | 2006 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 135.6M | 135.7M |
| IPO Year | 2017 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NCSM | CNTB |
|---|---|---|
| Price | $49.83 | $2.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.67 |
| AVG Volume (30 Days) | 5.3K | ★ 345.5K |
| Earning Date | 04-29-2026 | 08-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 239.22 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $142,471,000.00 | $64,000.00 |
| Revenue This Year | $5.57 | N/A |
| Revenue Next Year | $4.81 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $34.06 | $1.23 |
| 52 Week High | $87.36 | $3.82 |
Technical Indicators
Market Signals| Indicator | NCSM | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 55.55 | 51.02 |
| Support Level | $42.69 | $2.30 |
| Resistance Level | $51.69 | $2.69 |
| Average True Range (ATR) | 1.26 | 0.16 |
| MACD | 0.11 | 0.01 |
| Stochastic Oscillator | 69.45 | 45.00 |
Price Performance
Historical ComparisonAbout NCSM NCS Multistage Holdings Inc.
NCS Multistage Holdings Inc is a provider of engineered products and support services that facilitate the optimization of oil and natural gas well construction, well completion, and field development strategies. The company provides its products and services to E&P companies for use in onshore and offshore wells, predominantly those drilled with horizontal laterals in unconventional and conventional oil and natural gas formations. It also provides tracer diagnostics services and sells products for well construction including casing buoyancy systems, liner hanger systems and toe initiation sleeves, along with certain complementary products from third parties. The company operates in the United States, Canada and other countries, with the majority of its revenue generated from Canada.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.